Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide vs Empagliflozin in Early Type 2 Diabetes and Obesity
NCT05444153Phase 3Withdrawn
- Sponsor
- Novo Nordisk
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), obesity, sponsored by Novo Nordisk. Planned start Oct 2022; status: withdrawn.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05444153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05444153.